UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported) - November 17, 1998
CLARY CORPORATION
(Exact name of Registrant as specified in charter)
California 1-3489 95-0630196
(State or other (Commission File Number) (IRS Employer
incorporation) Identification No.)
1960 S. Walker Avenue, Monrovia, California 91016
(Address of principal executive offices)
Registrant's telephone number, including area code (626) 359-4486
(Former name or former address, if changed since last report)
Not applicable
<PAGE>
Item 5 - Other Events
Recently, the Registrant issued two press releases regarding significant
events:
1. Clary Corporation announced a $1.1 million dollar order from
Celera Genomics, a newly formed unit of Perkin Elmer (NYSE: PKN).
Celera Genomics will use Clary's 5 kVA E Series power supply as
back-up power on DNA analyzers. Celera Genomics intends to
become the definitive source of genomics and associated medical
information by compiling the bio-informatics tools and
scientific expertise necessary to extract biological knowledge
from genomic data. The Registrant expects continuing orders
from the ongoing programs.
2. Clary Corporation announced that its M1145 medical Uninterruptible
Power Supply (UPS) has received FDA 510(k) clearance for use with
patient ventilators in operating rooms and intensive care units.
The M1145 is the only UPS to pass FDA's newest and toughest EMI
(electromagnetic interference) and EMC (electromagnetic compati-
bility) specifications. Clary's M1145 is compatible with the
world's most widely used ventilator, the Puritan-Bennett 7200
Series by Mallinckrodt (NYSE: MKG). The significance of this
clearance is there are approximately 40,000 ventilators in
hospitals throughout the world with an additional 1,000 to 2,000
per year entering the market. Each of these ventilators is a
potential candidate for power back-up.
It is the opinion of management that these two new programs will allow
the Registrant the opportunity to achieve sufficient sales levels in
1999 so it will be able to return to profitable operations.
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
CLARY CORPORATION
John G. Clary
President
DATED: December 17, 1998
